title: Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1.
abstract: The tat gene product (Tat) of HIV-1 is an early regulatory protein necessary for viral gene expression and replication. Tat may also play a role as an extracellular protein in both HIV-1 replication and AIDS-associated disorders such as Kaposi's sarcoma. Thus, Tat represents a good target for gene therapy against AIDS. Here we show that when vectors expressing antisense tat RNA are transiently transfected into CD4+ cells, they block about 70% of HIV-1 replication and inhibit the rescue of Tat-defective HIV-1 proviruses by inhibition of Tat protein expression and consequent lack of transcriptional activation of the HIV-promoter. However, antisense tat vectors cannot block the activity of extracellular Tat protein. Another tat inhibitory construct (poly-Tat-activation response; TAR) previously suggested to inhibit HIV-1 transactivation by sequestering the Tat protein, inhibited the activity of extracellular Tat, but like antisense tat RNA did not completely block viral gene expression and replication. These results suggested that one mode of inhibition is not sufficient to block Tat function. However, when the antisense tat and the poly-TAR constructs were combined HIV-1 gene expression was completely blocked (94-98%), suggesting that a combination of inhibitory genes blocking Tat by sequential steps may be a better approach for AIDS gene therapy.
authors.affiliation: Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: H K
authors.initials: HK
authors.lastname: Chang
authors.forename: R
authors.initials: R
authors.lastname: Gendelman
authors.forename: J
authors.initials: J
authors.lastname: Lisziewicz
authors.forename: R C
authors.initials: RC
authors.lastname: Gallo
authors.forename: B
authors.initials: B
authors.lastname: Ensoli
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy; D016375:Antisense Elements (Genetics) / Q000235:genetics; D001483:Base Sequence; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D002460:Cell Line; D015870:Gene Expression / Q000187:drug effects; D015756:Genes, tat; D015316:Genetic Therapy; D015658:HIV Infections / Q000517:prevention & control* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D006367:HeLa Cells; D006801:Humans; D008969:Molecular Sequence Data; D010957:Plasmids / Q000235:genetics; D016372:RNA, Antisense / Q000235:genetics / Q000494:pharmacology*; D014162:Transfection; D014779:Virus Replication / Q000187:drug effects / Q000235:genetics
chemical_list: D016375:Antisense Elements (Genetics); D016372:RNA, Antisense